NextCure S-4 Amendment Reveals $820M Avere Financing and Section 205 Action
NXTC has more than doubled off its 52-week low of $1.55.
Summary
NextCure's amended S-4 reveals the Avere pre-closing financing has grown to $820 million and discloses a Section 205 Action to validate its 2025 reverse stock split. Legacy stockholders will own ~1.04% of the combined company.
Key Events · M&A and Partnerships · NXTC
-
Avere Financing Grows to $820M
The Avere pre-closing financing increased from $320 million to $820 million via a $500 million Subscription Agreement Amendment. Additional commitments priced at $27.6621 per share, 282% of the initial $9.8093 price, implying a $705 million pre-money Avere valuation.
-
Legacy Stockholders Diluted to ~1.04%
Based on the estimated exchange ratio of 6.5600 and NextCure net cash of approximately $(2.3) million, legacy NextCure securityholders will own approximately 1.04% of the combined company post-merger on a fully diluted basis.
-
Section 205 Action Filed
NextCure filed a Section 205 petition on September 14, 2026 seeking validation of its 2025 reverse stock split after discovering the vote may have fallen short. An adverse outcome could delay or prevent the merger.
-
Re-Domiciliation Mechanism Changed
The amendment changes the re-domiciliation from a charter amendment to a conversion of NextCure from a Delaware corporation into a Texas corporation, with the name change to Avere Therapeutics, Inc.
Analysis · NXTC · Life Sciences
This Amendment No. 1 to the S-4 materially updates the reverse merger with Avere Therapeutics. The Avere pre-closing financing has grown from $320 million to $820 million via a $500 million amendment priced at $27.6621 per share — 282% of the initial $9.8093 price — reflecting unanticipated investor demand. Legacy NextCure stockholders will own only ~1.04% of the combined company post-merger. The filing also discloses the Section 205 Action filed September 14, 2026 to validate the 2025 reverse stock split, creating uncertainty about NextCure's capitalization that could delay or prevent the merger. The re-domiciliation mechanism has changed from a charter amendment to a conversion from Delaware to Texas.
How filings like this one have moved
In the 30 days to Oct 19, 2026, 43.2% of the 271 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.30%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NXTC was trading at $5.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22.9M. The 52-week trading range was $1.55 to $15.74. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.